Rep. Morgan Griffith

R

Virginia – District 9
representative

Leadership

Chairman Health

119th Congress

News & Announcements

Jul 16, 2025
Press Release

Chairman Griffith Delivers Opening Statement at Subcommittee on Health Hearing on Preserving Access to Timely and Affordable Care

WASHINGTON, D.C.  – Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Health, delivered the following opening statement at today’s hearing titled Legislative Proposals to Maintain and Improve the Public Health Workforce, Rural Health, and Over-the-Counter Medicines. Subcommittee Chairman Griffith’s opening statement as prepared for delivery: “Today’s legislative hearing is necessary to continue essential programs that are vital to our health care infrastructure.  “Many of the bills before us expire at the end of this fiscal year and must be reauthorized.   “One of the bills that will be discussed today is H.R. 4273, the Over-the-Counter Monograph Drug User Fee Amendments, led by Mr. Latta and Ranking Member DeGette.   “The Coronavirus Aid, Relief, and Economic Security (CARES) Act, which passed in 2020, modernized the regulation of over-the-counter monograph drugs and products. It also created a new user fee program to support this new framework, also known as OMUFA.   “Generally, a company can market an over-the-counter drug if they either submit a new drug application or go through the over-the-counter monograph process.   “Prior to 2020, this involved a lengthy, burdensome three-phase, rulemaking process.  “This led to Congress creating a new regulatory framework that allows FDA to issue administrative orders determining that a product is generally recognized as safe and effective, or GRASE, and simultaneously establishing a new user fee program to help ensure this process is effective and streamlined.   “This is the first reauthorization of OMUFA.  “We hope to work in a bipartisan way to address any outstanding issues to ensure this program is functioning how Congress initially intended, including minimizing regulatory burdens, supporting innovation, and increasing access to products in a safe and efficient manner.   “We will also consider other legislation that will help encourage the FDA to be more flexible in their review processes.   “H.R. 3686, the SAFE Sunscreen Standards Act, led by Dr. Joyce and Mrs. Dingell, would require the FDA to consider the use of certain real-world, evidence-based and non-animal testing methods when it comes to evaluating new sunscreen active ingredients in the United States.   “We are behind other countries in bringing innovative sunscreens to market, and this bill would help to bridge that gap.  “During our last hearing on OMUFA, we had a robust discussion around the need for more innovative sunscreens to be available in the United States.   “I look forward to the discussion around these policies today.  “Along similar lines, the FDA must keep pace with current technological advancements, which includes greater utilization of non-animal testing methods.   “H.R. 2821, led by Reps. Carter and Barragan, would help support FDA’s efforts to do just that.   “Congress gave FDA this ability in 2022 when the FDA Modernization 2.0 was signed into law, but the FDA has failed to fully implement these practices.   “This legislation would require the FDA to finally update its regulations to account for non-animal testing. “This bill does not require non-animal testing; it simply provides the option if companies wish to pursue less costly methods, such as computer AI modeling or organ chip testing.   “There are also two important reauthorizations in front of us today that serve a vital role in helping our medical workforce, which are the Title VII and Title VIII reauthorizations.   “These programs allocate resources for scholarships and educational assistance, so students from underserved backgrounds, who are often from rural areas, can pursue medical careers and help support the medical workforce that Americans widely rely upon.   “It is crucial for Congress to take a close look at these programs to ensure resources are going to areas and patients who need it most.  “We are also discussing legislation that will continue grants for certain health care services in rural areas and help to increase the use of telehealth, so patients can access care more easily.  “Reauthorizing the Telehealth Resource Centers Grant Program will support our telehealth infrastructure that has become a lifeline for both providers and patients across the country– especially in rural areas.   “Considering each of these reauthorizations is an important step forward to ensure each program is working as intended.  “I look forward to hearing from our witnesses today regarding the importance of these programs, and to ensure they are reauthorized in a timely manner.”   ###

Jul 15, 2025
Press Release

Committee on Energy and Commerce Enacts Changes to Subcommittee Leadership and Memberships

WASHINGTON, D.C.  – Today, Congressman Brett Guthrie (KY-02), Chairman of the Committee on Energy and Commerce, led a Full Committee Business Meeting to enact new subcommittee leadership and changes to subcommittee membership.   The following changes to Subcommittee leadership and rosters were enacted:  Rep. Earl L. “Buddy” Carter (GA-01) will leave the Chairmanship of the Subcommittee on Health to focus on other priorities.  Rep. Morgan Griffith (VA-09) has been appointed to Chairman of the Subcommittee on Health.  Rep. Gary Palmer (AL-06) has been appointed to Chairman of the Subcommittee on Environment.  Rep. John Joyce (PA-13) has been appointed to Chairman of the Subcommittee on Oversight and Investigations.  Rep. Neal Dunn (FL-02) has been appointed to Vice Chairman of the House Committee on Energy and Commerce.  Rep. Diana Harshbarger (TN-01) has been appointed to Vice Chair of the Subcommittee on Health.  The new Subcommittee Rosters are as follows:  Subcommittee on Commerce, Manufacturing, & Trade:  Rep. Gus Bilirakis (FL-12), Chairman  Rep. Russ Fulcher (ID-01), Vice Chairman  Rep. Neal Dunn (FL-02)   Rep. Kat Cammack (FL-03)   Rep. Jay Obernolte (CA-23)   Rep. John James (MI-10)   Rep. Cliff Bentz (OR-02)   Rep. Erin Houchin (IN-09)   Rep. Russell Fry (SC-07)   Rep. Laurel Lee (FL-15)   Rep. Tom Kean, Jr. (NJ-07)    Rep. Gabe Evans (CO-08)    Rep. Craig Goldman (TX-12)  Rep. Brett Guthrie (KY-02), Ex-Officio  Subcommittee on Communications and Technology:  Rep. Richard Hudson (NC-09), Chairman  Rep. Rick Allen (GA-12), Vice Chairman  Rep. Bob Latta (OH-05)   Rep. Morgan Griffith (VA-09)  Rep. Gus Bilirakis (FL-12)   Rep. Buddy Carter (GA-01)   Rep. Neal Dunn (FL-02)   Rep. Russ Fulcher (ID-01)   Rep. August Pfluger (TX-11)   Rep. Kat Cammack (FL-03)   Rep. Jay Obernolte (CA-23)   Rep. Erin Houchin (IN-09)   Rep. Russell Fry (SC-07)   Rep. Tom Kean, Jr. (NJ-07)    Rep. Craig Goldman (TX-12)   Rep. Julie Fedorchak (ND-AL)  Rep. Brett Guthrie (KY-02), Ex-Officio  Subcommittee on Energy:  Rep. Bob Latta (OH-05), Chairman  Rep. Randy Weber (TX-14), Vice Chairman  Rep. Gary Palmer (AL-06)   Rep. Rick Allen (GA-12)   Rep. Troy Balderson (OH-12)   Rep. August Pfluger (TX-11)   Rep. Diana Harshbarger (TN-01)   Rep. Mariannette Miller-Meeks (IA-01)   Rep. John James (MI-10)   Rep. Cliff Bentz (OR-02)   Rep. Russell Fry (SC-07)   Rep. Laurel Lee (FL-15)   Rep. Nick Langworthy (NY-23)   Rep. Michael Rulli (OH-06)   Rep. Gabe Evans (CO-08)   Rep. Craig Goldman (TX-12)   Rep. Julie Fedorchak (ND-AL)  Rep. Brett Guthrie (KY-02), Ex-Officio  Subcommittee on Environment:  Rep. Gary Palmer (AL-06), Chairman  Rep. Dan Crenshaw (TX-02), Vice Chairman  Rep. Bob Latta (OH-05)    Rep. Morgan Griffith (VA-09)   Rep. Buddy Carter (GA-01)   Rep. John Joyce (PA-13)   Rep. Randy Weber (TX-14)   Rep. August Pfluger (TX-11)   Rep. Mariannette Miller-Meeks (IA-01)   Rep. Laurel Lee (FL-15)   Rep. Nick Langworthy (NY-23)   Rep. Gabe Evans (CO-08)   Rep. Julie Fedorchak (ND-AL)  Rep. Brett Guthrie (KY-02), Ex-Officio  Subcommittee on Health:  Rep. Morgan Griffith (VA-09), Chairman  Rep. Diana Harshbarger (TN-01), Vice Chair  Rep. Gus Bilirakis (FL-12)   Rep. Buddy Carter (GA-01)   Rep. Neal Dunn (FL-02)    Rep. Dan Crenshaw (TX-02)   Rep. John Joyce (PA-13)   Rep. Troy Balderson (OH-12)   Rep. Mariannette Miller-Meeks (IA-01)   Rep. Kat Cammack (FL-03)   Rep. Jay Obernolte (CA-23)   Rep. John James (MI-10)   Rep. Cliff Bentz (OR-02)   Rep. Erin Houchin (IN-09)   Rep. Nick Langworthy (NY-23)   Rep. Tom Kean, Jr. (NJ-07)    Rep. Michael Rulli (OH-06)  Rep. Brett Guthrie (KY-02), Ex-Officio  Subcommittee on Oversight & Investigations:  Rep. John Joyce (PA-13), Chairman  Rep. Troy Balderson (OH-12), Vice Chairman  Rep. Gary Palmer (AL-06)  Rep. Dan Crenshaw (TX-02)  Rep. Randy Weber (TX-14)  Rep. Rick Allen (GA-12)  Rep. Russ Fulcher (ID-01)  Rep. Diana Harshbarger (TN-01)  Rep. Michael Rulli (OH-06)  Rep. Brett Guthrie (KY-02), Ex-Officio  ###

Jul 9, 2025
Press Release

Chairman Guthrie and Chairman-Designate Griffith Announce Legislative Hearing on Preserving Access to Timely and Affordable Care

WASHINGTON, D.C.  – Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman Morgan Griffith (VA-09), Chairman-Designate of the Subcommittee on Health, announced a hearing titled Legislative Proposals to Maintain and Improve the Public Health Workforce, Rural Health, and Over-the-Counter Medicines.   "These vital public health programs play a critical role in improving health care for Americans,” said Chairman Guthrie and Chairman-Designate Griffith . “Programs like the Over-the-Counter Monograph Drug User Fee Program are crucial to ensure patient access to safe over-the-counter products. The Health Subcommittee remains committed to priorities like bolstering health care workforce development, as well as lifting up rural communities to ensure all Americans can live healthier lives."   Subcommittee on Health hearing titled Legislative Proposals to Maintain and Improve the Public Health Workforce, Rural Health, and Over-the-Counter Medicines.   WHAT: Subcommittee on Health Hearing on Preserving Access to Timely and Affordable Care.  DATE: Wednesday, July 16, 2025  TIME: 10:00 AM ET LOCATION: 2123 Rayburn House Office Building.  This notice is at the direction of the Chairman. The hearing will be open to the public and press and will be livestreamed online at energycommerce.house.gov . If you have any questions concerning this hearing, please contact Annabelle Huffman at Annabelle.Huffman@mail.house.gov . If you have any press-related questions, please contact Katie West at Katie.West@mail.house.gov .   ###

Letters

Apr 11, 2025
Press Release

Chairmen Guthrie, Palmer, and Griffith Investigate Greenhouse Gas Reduction Fund Grant Recipients

WASHINGTON, D.C. – This week, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, Congressman Gary Palmer (AL-06), Chairman of the Subcommittee on Oversight and Investigations, and Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Environment, wrote letters to eight Greenhouse Gas Reduction Fund (GGRF) grant recipients. “The Committee has had concerns about the GGRF program—including the program’s unusual structure and a potential lack of due diligence in selecting award recipients. A recent Oversight and Investigations Subcommittee hearing examined these issues and the speed with which money was pushed out the door by the Biden Administration’s EPA, which raised additional questions about certain GGRF recipients.” said Chairmen Guthrie, Palmer, and Griffith. “ This investigation is key to evaluating whether these funds were awarded fairly and impartially to qualified applicants and determining how the federal funds are being used.” Background:  The Inflation Reduction Act (IRA) authorized the Environmental Protection Agency (EPA) to create and implement a $27 billion GGRF program. Of this appropriation, $20 billion was awarded to just eight grant recipients; with $14 billion awarded to three grant recipients under the National Clean Investment Fund (NCIF) program and $6 billion awarded to five grant recipients under the Clean Communities Investment Accelerator (CCIA) program.    Letters: National Clean Investment Fund Program Recipients Coalition for Green Capital Climate United Fund Power Forward Communities   Clean Communities Investment Accelerator Program Recipients Justice Climate Fund Opportunity Finance Network Inclusiv Native CDFI Network Appalachian Community Capital Read the story here . ###

Dec 19, 2024
Press Release

E&C Republicans Request HHS Watchdog Investigate Promotion of Gender Transition Procedures for Children

Washington, D.C. — In a new letter to Department of Health and Human Services (HHS) Inspector General Christi Grimm, House Energy and Commerce Committee Republicans requested an investigation into the strength, quality, and types of evidence-based scientific and pediatric medical literature relied on by the department to promote gender transition procedures for children.  KEY LETTER EXCERPT:  “As the agency responsible for safeguarding the health and well-being of Americans, all of HHS’s medical treatment recommendations, especially medical treatment recommendations for children, should be based on rigorous and well-established research, such as randomized controlled trials, that have definitively illustrated the long-term benefits of gender affirming care treatments.”  BACKGROUND:  Under the Biden administration, HHS has advocated for sex reassignment procedures on minors, including the use of serum puberty blockers, which have historically been used to treat children with precocious puberty (i.e., early onset puberty affecting about one percent of U.S. children) and sex offenders.   Puberty blockers, however, are known to stunt normal childhood development in children unaffected by precocious puberty.  HHS officials contend that sex reassignment procedures on minors are an unanimously accepted medical practice.  HHS Secretary Becerra testified before Congress that “every major medical association,” “medical journals,” and “scientific and medical evidence” has demonstrated the benefits of transitioning children’s biological sex.  When asked, via a Freedom of Information Act request, for the underlying scientific or medical basis for its position, HHS was only able to produce a two-page brochure that was already publicly available.  In contrast to HHS, a growing body of literature from medical experts and authorities around the world, including those in Europe, caution against performing such procedures on minors.   Courts and government health agencies responsible for determining child welfare have sought to limit child sex reassignment procedures.   Other countries have banned these interventions and surgeries on minors altogether.  An article published in the British Journal of Medicine found “there is great uncertainty about the effects of puberty blockers, cross-sex hormones, and surgeries in young people.”   A court in the United Kingdom noted the obvious about administering puberty blocking chemicals onto children: “[i]t is highly unlikely that a child aged 13 or under would be competent to give consent to the administration of puberty blockers. It is doubtful that a child aged 14 or 15 could understand and weigh the long-term risks and consequences of the administration of puberty blockers.”  In April 2024, the Cass Review , an independent review of gender identity services for children and young people, commissioned by the National Health Service England, found “[w]hile a considerable amount of research has been published in this field, systematic evidence reviews demonstrated the poor quality of the published studies, meaning there is not a reliable evidence base upon which to make clinical decisions, or for children and their families to make informed choices.”   The Cass Review also found that “[t]he rationale for early puberty suppression remains unclear, with weak evidence regarding the impact on gender dysphoria, mental or psychosocial health,” as well as unknown effects on cognitive and psychosexual development.  In August 2024, the American Society of Plastic Surgeons (ASPS) became the first major U.S. medical association to express caution on the use of gender surgery for gender dysphoria in adolescents. In its formal statement, the association stated: “ASPS currently understands that there is considerable uncertainty as to the long-term efficacy for the use of chest and genital surgical interventions for the treatment of adolescents with gender dysphoria, and the existing evidence base is viewed as low quality/low certainty. This patient population requires specific considerations.”   The letter was signed by Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), Rep. Dan Crenshaw (R-TX), Rep. Gus Bilirakis (R-FL), Rep. Buddy Carter (R-GA), Rep. Gary Palmer (R-AL), Rep. Neal Dunn (R-FL), Rep. Randy Weber (R-TX), Rep. Troy Balderson (R-OH), Rep. August Pfluger (R-TX), Rep. Diana Harshbarger (R-TN), and Rep. Kat Cammack (R-FL).  CLICK HERE to read the letter.

Nov 22, 2024
Press Release

E&C, E&W Republicans Press Gladstone Institutes for Information Regarding Internal Antisemitism

House Republicans scrutinize government grant funding recipients that fail to protect individuals from antisemitism Washington, D.C. — In a new letter to J. David Gladstone Institutes President Dr. Deepak Srivastava, the House Committee on Energy and Commerce (E&C) and House Committee on Education and the Workforce (E&W) have requested information about ongoing and pervasive acts of antisemitic harassment and intimidation at Gladstone and its leadership’s insufficient response to these acts. The letter is signed by E&C Chair Cathy McMorris Rodgers (R-WA), E&C Subcommittee on Health Chair Brett Guthrie (R-KY), E&C Oversight and Investigations Subcommittee Chair Morgan Griffith (R-VA), E&W Chair Virginia Foxx (R-NC), and E&W Subcommittee on Higher Education and Workforce Development Chair Burgess Owens (R-UT).  KEY LETTER EXCERPTS: “The Gladstone Institutes, an independent biomedical research organization, claims that it takes an active stance against serious issues like discrimination and harassment and aims to ‘ensure all community members at Gladstone feel included’ and that the Institutes will aim to ‘implement accountability measures and reinforce Gladstone’s commitment to having an environment free of harassment.’ However, these values do not seem to be reflected in the actions of leadership in response to recent concerns of antisemitic harassment and discrimination within the Institutes.” [...] “The reports of antisemitic harassment at Gladstone coupled with the inadequate response by leadership is concerning to the Committees. Failing to act decisively to ensure a safe environment for all trainees, faculty, and staff is a grave dereliction of your responsibilities as President of Gladstone.” “Failing to comply with basic safety protections for members of Gladstone or failure to respond appropriately to and prevent harassment and discrimination, no matter the cause, may be grounds to withhold federal funds from the university. Congress has an obligation to exercise oversight of recipients of federal funds when blatant and ongoing Title VI violations appear to be happening. If Congress determines an institution of higher education/research is blatantly ignoring its legal responsibilities, we may consider rescinding research and development funds previously appropriated.” BACKGROUND ON TAXPAYER FUNDING: Gladstone received more than $41 million in funding from the NIH in Fiscal Year 2023, not including potential taxpayer funding that individual faculty may have received through their affiliation with the University of California, San Francisco (UCSF) or any other affiliated universities.   According to the NIH’s Grant Policy Statement, any institution receiving federal funds must assure work environments are free of discriminatory harassment and are safe and conducive to high-quality work.  Institutions receiving federal taxpayer financial assistance—such as NIH grants—are prohibited from discriminating based on a variety of categories, including national origin.   These laws also protect members of the institution who are or are perceived to be members of a group with shared ancestry, such as students/trainees of Jewish heritage. BACKGROUND ON INSTANCES OF ANTISEMITISM : Two days after the October 7, 2023, Hamas terrorist attack, a graduate student working in a lab within Gladstone sent an antisemitic email to all Gladstone faculty, trainees, and staff falsely stating that the attack on innocent Israeli civilians was “the resistance in Gaza launch[ing] a surprise attack against Israel, taking occupation soldiers hostage, taking over Israeli military vehicles, and gain[ing] control over illegal Israeli settlements.”  The email goes on to claim that all casualties resulting from Palestinian actions are the responsibility of Israel.  Immediately following this mass email, members of the Gladstone faculty began contacting the Gladstone Institutes’ President and other leadership, appalled by the language of the email, concerned for their safety and worried that the email could be seen as an incitement to violence.  Jewish members of the Institutes also expressed their deep, personal pain following the Hamas attack, as some members had family or friends reported killed or missing directly after the attack.  These fears—including fears of being attacked in the lab by the author of this cruel and antagonistic email—were shared directly with President Srivastava.  Despite this, Gladstone leadership did not issue a public statement or position against antisemitism to quell fears of Jewish faculty and trainees.  In May 2024, the Center for Combatting Antisemitism sent President Srivastava a letter requesting administrative action to address the hostile environment and disparate treatment of Jewish members at Gladstone.  This letter noted that Gladstone refused to acknowledge Jewish American Heritage Month, Passover, or Holocaust Remembrance Day, despite sending official celebratory emails and holding events for other religious, ethnic, or national holidays, including Black History Month, International Women’s Day, and Ramadan.  The Center followed up with Gladstone several times, but never received a response.  Jewish faculty and trainees have conveyed to leadership within Gladstone instances of antisemitic harassment and discrimination, which faculty and trainees believe were not taken seriously, making some feel uneasy about speaking out.  For example, per a publicly available Fair Employment and Housing Act complaint to the California Civil Rights Division, a Jewish faculty member openly discussed fellow faculty using racial stereotypes, including comments about a “Jewish nose.”  When these comments were brought to human resources, no investigation occurred.  Instead, the complainant was subsequently targeted with an investigation ultimately deemed to be unwarranted.  Then, following the complainant’s post-October 7th advocacy on behalf of Jewish faculty and trainees, the complainant was threatened repeatedly with career-ending termination, allegedly in an attempt to extort a resignation.  When the threats did not have their desired effect, Gladstone placed the complainant on administrative leave and removed the complainant’s electronic access to email and files but also physical access to the complainant’s lab, removing all ability to conduct work on an NIH-funded grant.  Gladstone ultimately paid an undisclosed sum to settle the matter and avoid litigation.  To elevate concerns regarding widespread, ongoing discrimination, Jewish faculty and trainees requested permission to bring in a speaker related to antisemitism.  Other minority groups had previously been given permission to bring in similar anti-racism speakers.  However, while leadership stated it would look into the idea, ultimately no speaker was brought, and no program was launched regarding antisemitism. BACKGROUND ON AFFILIATIONS WITH OTHER INSTITUTIONS UNDER INVESTIGATION : Gladstone Institutes is affiliated with other institutions under congressional investigation.  For example, Gladstone is an affiliate of the UCSF, which is undergoing congressional investigation for reports of antisemitism within the university, medical school, and medical centers.  Most of Gladstone’s principal investigators are also faculty at UCSF, and the Institutes provide research positions and opportunities for graduate students from UCSF.  Moreover, there is a joint institute—the Gladstone-UCSF Institute of Genomic Immunology—further linking the two institutions.  Gladstone is also affiliated with the University of California, Berkeley and Stanford University, both of which are also under investigation for concerns related to antisemitism. CLICK HERE to read the full letter.